Fusion Antibodies (FAB) Competitors GBX 16.50 -1.20 (-6.78%) As of 12:02 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock FAB vs. ETX, SBTX, COS, C4XD, DDDD, FUM, TRX, AREC, OKYO, and AORShould you be buying Fusion Antibodies stock or one of its competitors? The main competitors of Fusion Antibodies include e-therapeutics (ETX), SkinBioTherapeutics (SBTX), Collagen Solutions plc (COS.L) (COS), C4X Discovery (C4XD), 4D pharma (DDDD), Futura Medical (FUM), Tissue Regenix Group (TRX), Arecor Therapeutics (AREC), OKYO Pharma (OKYO), and AorTech International (AOR). These companies are all part of the "biotechnology" industry. Fusion Antibodies vs. Its Competitors e-therapeutics SkinBioTherapeutics Collagen Solutions plc (COS.L) C4X Discovery 4D pharma Futura Medical Tissue Regenix Group Arecor Therapeutics OKYO Pharma AorTech International e-therapeutics (LON:ETX) and Fusion Antibodies (LON:FAB) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, media sentiment, earnings and valuation. Which has more risk & volatility, ETX or FAB? e-therapeutics has a beta of 0.46, indicating that its share price is 54% less volatile than the S&P 500. Comparatively, Fusion Antibodies has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500. Does the media refer more to ETX or FAB? In the previous week, e-therapeutics' average media sentiment score of 0.00 equaled Fusion Antibodies'average media sentiment score. Company Overall Sentiment e-therapeutics Neutral Fusion Antibodies Neutral Which has higher valuation and earnings, ETX or FAB? Fusion Antibodies has higher revenue and earnings than e-therapeutics. Fusion Antibodies is trading at a lower price-to-earnings ratio than e-therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratioe-therapeutics£295K0.00-£10.06M-£0.02N/AFusion Antibodies£2.09M7.41-£4.10M-£4.45-3.71 Do insiders and institutionals have more ownership in ETX or FAB? 26.5% of e-therapeutics shares are owned by institutional investors. Comparatively, 21.0% of Fusion Antibodies shares are owned by institutional investors. 59.4% of e-therapeutics shares are owned by insiders. Comparatively, 11.4% of Fusion Antibodies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is ETX or FAB more profitable? e-therapeutics has a net margin of 0.00% compared to Fusion Antibodies' net margin of -195.95%. e-therapeutics' return on equity of -38.75% beat Fusion Antibodies' return on equity.Company Net Margins Return on Equity Return on Assets e-therapeuticsN/A -38.75% -29.10% Fusion Antibodies -195.95%-137.11%-63.78% Summarye-therapeutics beats Fusion Antibodies on 6 of the 10 factors compared between the two stocks. Get Fusion Antibodies News Delivered to You Automatically Sign up to receive the latest news and ratings for FAB and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FAB vs. The Competition Export to ExcelMetricFusion AntibodiesBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£15.52M£139.16M£5.70B£3.08BDividend YieldN/A3.74%3.77%5.04%P/E Ratio-3.713.8430.86171.50Price / Sales7.414,315.74403.88290,516.98Price / Cash9.0213.1925.2227.94Price / Book4.7049.779.515.58Net Income-£4.10M-£90.99M£3.26B£5.89B7 Day Performance16.20%3.41%4.50%0.23%1 Month Performance101.47%6.10%5.22%0.43%1 Year Performance392.54%184.19%31.92%72.36% Fusion Antibodies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FABFusion AntibodiesN/AGBX 16.50-6.8%N/A+428.4%£15.52M£2.09M-3.7148High Trading VolumeETXe-therapeuticsN/AN/AN/AN/A£52.59M£295K-450.0035High Trading VolumeSBTXSkinBioTherapeuticsN/AGBX 16.01-3.0%N/A+11.2%£36.56M£1.56M-9.8411COSCollagen Solutions plc (COS.L)N/AN/AN/AN/A£30.99M£4.01M-8.283,350C4XDC4X DiscoveryN/AN/AN/AN/A£30.27M£24.68M300.0049High Trading VolumeDDDD4D pharmaN/AN/AN/AN/A£30.05M£718K-1.08106Positive NewsFUMFutura MedicalN/AGBX 9.35-18.9%N/A-71.3%£29.14M£8.68M-7.7112News CoverageGap DownHigh Trading VolumeTRXTissue Regenix GroupN/AGBX 32-3.0%N/A-52.4%£28.85M£31.98M-33.04120Gap UpARECArecor TherapeuticsN/AGBX 62.10+5.3%N/A-31.0%£23.45M£6.04M-2.1910High Trading VolumeOKYOOKYO PharmaN/AN/AN/AN/A£23.24MN/A-140.007Gap DownAORAorTech InternationalN/AN/AN/AN/A£19.99M£539K-33.383 Related Companies and Tools Related Companies e-therapeutics Alternatives SkinBioTherapeutics Alternatives Collagen Solutions plc (COS.L) Alternatives C4X Discovery Alternatives 4D pharma Alternatives Futura Medical Alternatives Tissue Regenix Group Alternatives Arecor Therapeutics Alternatives OKYO Pharma Alternatives AorTech International Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:FAB) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredGENIUS Act: Cancel Your Money?They said digital dollars were off the table. But with the GENIUS Act now federal law, private corporations—no...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fusion Antibodies plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Fusion Antibodies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access